EMA/PE/0000232757
Submitted by Anonymous (not verified) on 2 July 2026 - 16:42
EMA/PE/0000232757
EMA/PE/0000182928
Submitted by Anonymous (not verified) on 2 July 2026 - 16:40
EMA/PE/0000182928
EMEA-003489-PIP01-23
Submitted by Anonymous (not verified) on 2 July 2026 - 16:38
EMEA-003489-PIP01-23
EMEA-003489-PIP02-23
Submitted by Anonymous (not verified) on 2 July 2026 - 16:38
EMEA-003489-PIP02-23
EMEA-003435-PIP02-23
Submitted by Anonymous (not verified) on 2 July 2026 - 16:36
EMEA-003435-PIP02-23
EMA/PE/0000232774
Submitted by Anonymous (not verified) on 2 July 2026 - 16:35
EMA/PE/0000232774
Human medicines European public assessment report (EPAR): Aquipta, atogepant, Date of authorisation: 11/08/2023, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 2 July 2026 - 16:30
Human medicines European public assessment report (EPAR): Aquipta, atogepant, Date of authorisation: 11/08/2023, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 15, Status: Authorised
Submitted by Anonymous (not verified) on 2 July 2026 - 15:55
Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 15, Status: Authorised
EMA steps up efforts on medicines for women’s health
Submitted by Anonymous (not verified) on 2 July 2026 - 13:30
EMA steps up efforts on medicines for women’s health
Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 28, Status: Authorised
Submitted by Anonymous (not verified) on 2 July 2026 - 13:30
Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 28, Status: Authorised